David Kerstein, Theravance's Chief Medical Officer, just received 150,000 options from the company. The strike price of the options received was $11.21, and these expire on February 17, 2032. Kerstein now owns at least 150,000 options on the company.
Some additional info was provided as follows:
The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the options vesting on February 18, 2023 and 1/48th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Theravance makes a similar move, sign up!